PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
ConditionGraft Versus Host Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorHenry Ford Health System
About this trial
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival , and overall survival
Eligibility criteria
Qualifiers
Patients with hematologic malignancy who have the indication for Allogeneic SCT and have no MRD or MUD.
Age 18-70 years old
Performance score of at least 80% by Karnofsky
Creatinine clearance should be >60 ml/min
Disqualifiers
Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause
Active or prior CNS leukemia, unless in complete remission for at least 2 months.
History of serious chronic mental disorder or drug-abuse accompanied by documented problems of compliance with therapeutic programs.
Uncontrolled infection
Trial design
Treatments tested in this trial
- uhCG/EGF
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov